Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine in Greece for Adults Aged ≥60 Years

OBJECTIVES: Respiratory syncytial virus (RSV) infections are one of the leading causes of lower respiratory tract disease (LRTD) among adults aged ≥60 years in Europe. Data in Europe show an annual incidence of 4–7% due to seasonal variations in older adults.

METHODS: A monthly-cycle static Markov model was developed to assess the impact of RSVPreF3 OA vaccine on adults 70 years and older and on adults 60–69 years with at least one underlying medical condition. The analysis was conducted from the healthcare system perspective, comparing no vaccination to a single dose of the RSV vaccine, considering vaccine effect over a three-year horizon and coverage of 30%. Local epidemiological and health care resource use data were used, supplemented by systematic literature reviews and relevant data from other countries. A 3.5% discount rate was assumed to costs and 0% to utilities. The incremental cost-effectiveness ratio (ICER) was calculated per quality-adjusted life-year (QALY). Deterministic and probabilistic sensitivity analyses were also conducted to assess robustness of the results.

RESULTS: Vaccinating adults 70+ years with 525,387 doses in total would avert 20,110 RSV-LRTD cases, 3,123 hospitalizations and 455 RSV-related deaths. Moreover, it would lead to a gain of 3,432 QALYs and prevent 24 million EUR direct medical costs. The ICER was estimated at 17,720/QALY gained. Vaccinating adults 60–69 years with at least one underlying medical condition with 209,356 doses in total would avert 8,349 RSV-LRTD cases, 1,440 hospitalizations and 106 RSV-related deaths. Moreover, it would lead to a gain of 1,813 QALYs and prevent 8 million EUR direct medical costs. The ICER was estimated at 13,196/QALY gained.

CONCLUSIONS: The RSV strategy is therefore cost-effective, in both population studies, compared to no vaccination and can alleviate the burden of RSV in Greece.